Drug-price Transparency for Consumers Act of 2023

Bill 118 s 1250, also known as the Drug-price Transparency for Consumers Act of 2023, aims to increase transparency in drug pricing for consumers. The bill requires pharmaceutical companies to provide detailed information on the pricing of their prescription drugs, including the cost of production, research and development expenses, and any other factors that contribute to the final price.

Additionally, the bill mandates that drug manufacturers disclose any price increases for their products, as well as any discounts or rebates offered to insurers or pharmacy benefit managers. This information must be made available to the public in a clear and easily accessible manner, such as on the company's website or through a government database.

The goal of the Drug-price Transparency for Consumers Act is to empower consumers to make more informed decisions about their healthcare and prescription drug purchases. By increasing transparency in drug pricing, the bill aims to hold pharmaceutical companies accountable for their pricing practices and help reduce the financial burden on patients. Overall, the bill seeks to promote fairness and affordability in the pharmaceutical industry, ultimately benefiting consumers and improving access to essential medications.